https://www.selleckchem.com/pr....oducts/bozitinib.htm
45 points for the PSQ and -6.44 points for the TICS-SSCS after 6 months. At 6-month follow-up the IG did not significantly differ from group B (PSQ p = 0.2332; TICS-SSCS p = 0.0805) or group C (PSQ p = 0.0950; TICS-SSCS p = 0.0607) when controlling for baseline (ANCOVA). Compared to group C, ANCOVA revealed significant differences in WHO-5 (p = 0.0292) and EQ-5D VAS (p = 0.0177) post intervention. At the 3- and 6-month follow-up and compared to group B, no substantial differences could be found for WHO-5 and EQ-5D VAS. The results ind
Like
Comment
Share
